297 filings
6-K
PRQR
ProQR Therapeutics N.V
23 Apr 24
Current report (foreign)
7:06am
6-K
PRQR
ProQR Therapeutics N.V
19 Apr 24
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
7:06am
20-F
2023 FY
PRQR
ProQR Therapeutics N.V
Annual report (foreign)
13 Mar 24
8:43am
6-K
PRQR
ProQR Therapeutics N.V
13 Mar 24
ProQR Announces Year End 2023 Operating and Financial Results
7:10am
6-K
PRQR
ProQR Therapeutics N.V
15 Feb 24
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
7:46am
SC 13G/A
4q3t9 3f6etlr2gx448t
14 Feb 24
ProQR Therapeutics / VAN HERK INVESTMENTS B.V. ownership change
6:08am
SC 13G/A
usprth1jiyatyy
9 Feb 24
ProQR Therapeutics / VAN HERK INVESTMENTS B.V. ownership change
6:37am
6-K
2ph 3p49nkhsgknxb1s
19 Jan 24
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
7:08am
6-K
u9ub9
5 Jan 24
Current report (foreign)
7:08am
6-K
ef31r
8 Dec 23
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
7:37am
6-K
nsd9kokr 7nzl2vz8
7 Nov 23
Current report (foreign)
10:00am
6-K
0snm0iv2 lk
27 Sep 23
ProQR Therapeutics Provides Update on Ophthalmic Assets
7:06am
SC 13G
p324 a9222
14 Sep 23
ProQR Therapeutics / VAN HERK INVESTMENTS B.V. ownership change
5:20pm
6-K
zgehntpp5to4y6
3 Aug 23
Current report (foreign)
7:15am
6-K
9iodsl96wjo
1 Aug 23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
7:15am
6-K
nkztfb1ghyg4zwzm
17 May 23
Current report (foreign)
4:05pm
6-K
uo853t91
16 May 23
Current report (foreign)
7:15am
EFFECT
e5wpx 2ypmwij
25 Apr 23
Notice of effectiveness
12:15am
424B5
0na58g5h6h2p729bnazb
24 Apr 23
Prospectus supplement for primary offering
4:30pm
CORRESP
mz5in8 dn
20 Apr 23
Correspondence with SEC
12:00am